152 related articles for article (PubMed ID: 26637849)
61. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
62. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.
Vereide AB; Arnes M; Straume B; Maltau JM; Ørbo A
Gynecol Oncol; 2003 Dec; 91(3):526-33. PubMed ID: 14675671
[TBL] [Abstract][Full Text] [Related]
63. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
64. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
65. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
66. The levonorgestrel intrauterine system for use in peri- and postmenopausal women.
Sitruk-Ware R
Contraception; 2007 Jun; 75(6 Suppl):S155-60. PubMed ID: 17531609
[TBL] [Abstract][Full Text] [Related]
67. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
68. BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.
Trabzonlu L; Muezzinoglu B; Corakci A
Pathol Oncol Res; 2019 Apr; 25(2):471-476. PubMed ID: 29270778
[TBL] [Abstract][Full Text] [Related]
69. Comparing the effects of intrauterine progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy.
Pirimoglu ZM; Ozyapi AG; Kars B; Buyukbayrak EE; Solak Y; Karsidag AY; Unal O; Turan MC
J Obstet Gynaecol Res; 2011 Oct; 37(10):1376-81. PubMed ID: 21599801
[TBL] [Abstract][Full Text] [Related]
70. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
Hampton NR; Rees MC; Lowe DG; Rauramo I; Barlow D; Guillebaud J
Hum Reprod; 2005 Sep; 20(9):2653-60. PubMed ID: 15905289
[TBL] [Abstract][Full Text] [Related]
71. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
[TBL] [Abstract][Full Text] [Related]
72. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
Depypere H; Inki P
Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
[TBL] [Abstract][Full Text] [Related]
73. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
[TBL] [Abstract][Full Text] [Related]
74. Regression of latent endometrial precancers by progestin infiltrated intrauterine device.
Ørbo A; Rise CE; Mutter GL
Cancer Res; 2006 Jun; 66(11):5613-7. PubMed ID: 16740697
[TBL] [Abstract][Full Text] [Related]
75. Effects of levonorgestrel-releasing intrauterine system on lymphangiogenesis of adenomyosis.
Cho S; Choi YS; Yun BH; Chon SJ; Jung YS; Kim H; Park JH; Seo SK; Kim SH; Lee BS
Am J Clin Pathol; 2015 Mar; 143(3):352-61. PubMed ID: 25696793
[TBL] [Abstract][Full Text] [Related]
76. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia.
Milam MR; Soliman PT; Chung LH; Schmeler KM; Bassett RL; Broaddus RR; Lu KH
Int J Gynecol Cancer; 2008; 18(1):146-51. PubMed ID: 17466036
[TBL] [Abstract][Full Text] [Related]
77. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
78. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
79. The study design and compliance may affect strength of inferences.
Gallos ID; Gupta JK
Am J Obstet Gynecol; 2012 Dec; 207(6):e9-e10; author reply e10. PubMed ID: 22901980
[No Abstract] [Full Text] [Related]
80. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
